ClinicalTrials.gg
WithdrawnNCT03048136CheckMate 955Updated Apr 17, 2018

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

A Phase 3 interventional study of Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business objective has changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
114th of 120
0 · median 66
Started
2018
with 14 others
Phase 3
24 of 120
3 open now
Registered
37th of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 114th largest by enrollment, is one of 15 that started in 2018, is one of 24 in phase 3, and was the 37th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

Read the detailed description

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

    1. Stage IV or recurrent non-Small cell lung cancer
    1. (ECOG) Performance Status of 0-1
    1. Prior or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization

Exclusion criteria

Exclusion Criteria:

    1. Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
    1. Active, known or suspected disease or infection
    1. Prior treatment with any drug that targets T cell co-stimulation pathways (such as )
    1. Untreated Central Nervous System

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Flat-Dose

    Nivolumab flat dose + Ipilimumab

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Weight-Based Dose

    Nivolumab weight-based dose + Ipilimumab

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified days

    Also known as: BMS-734016, Yervoy

06

What researchers measure

Primary outcomes

  1. Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events

    Time frame: Approximately 3 months

  2. Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events

    Time frame: Approximately 3 months

Secondary outcomes

  1. Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 24 months

  2. Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 24 months

  3. Overall survival (OS) as defined as the time from first dosing to the date of death

    Time frame: Up to 5 years

  4. Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 24 months

07

Study locations

17 sites
  • Local Institution
    San Francisco, California 94115, United States
  • Local Institution
    Lincoln, Nebraska 68506, United States
  • Local Institution
    Hackensack, New Jersey 07601, United States
  • Local Institution
    Columbus, Ohio 43210, United States
  • Local Institution
    Lancaster, Pennsylvania 17604, United States
  • Local Institution
    Langhorne, Pennsylvania 19047, United States
  • Local Institution
    Sayre, Pennsylvania 18840, United States
  • Local Institution
    Charleston, South Carolina 29414, United States
  • Local Institution
    Saint George, Utah 84770, United States
  • Local Institution
    Viedma, RIO Negro 8500, Argentina
  • Local Institution
    Montreal, Quebec H1M 1B1, Canada
  • Local Institution
    Dresden, 01307, Germany
  • Local Institution
    Gauting, 82131, Germany
  • Local Institution
    Gerlingen, 70839, Germany
  • Local Institution
    Grosshansdorf, 22927, Germany
  • Local Institution
    Lima, 27, Peru
  • Local Institution
    Lima, Peru
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2018; primary completion for Sep 2019, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2017
First posted
Feb 9, 2017
StartEst.
Mar 9, 2018
Primary completionEst.
Sep 29, 2019
CompletionEst.
Sep 29, 2019
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03048136
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Mar 9, 2018 (estimated)
Primary completion
Sep 29, 2019 (estimated)
Completion
Sep 29, 2019 (estimated)
Last update
Apr 17, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion